Covid-19… The Dilemmas of a Cardiologist!
Main Article Content
Abstract
The world is witnessing the devastations of SARS-CoV-2 pandemic. It is spreading fast and decimating the society due to high secondary attack rates and high virulence. Patients with known cardiovascular diseases are at an even greater risk of adverse outcomes and mortality by this infection. Also, Covid-19 may present with a multitude of cardiovascular manifestations. This challenges the cardiologists in making the right diagnosis and providing an adequate treatment to these patients, while protecting themselves too from acquiring the infection. Another concern is the dramatic fall in the number of acute coronary syndrome patients reaching the cardiology ER. This makes the patients devoid of the mortality advantage primary percutaneous intervention offers. Lack of definitive treatment and vaccine makes preventive strategy as the most important part while dealing with Covid-19. In this article, the authors summarise the various cardiovascular manifestations of Covid-19 and precautions needed while handling them.
Downloads
Article Details
Copyright (c) 2020 Prachi S, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 323: 1239-1242. Link: https://bit.ly/3cZYLea
Huang C, Wang Y, Li X, Ren L, Zha J, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. Link: https://bit.ly/2z7aZ5R
Inciardi RM, Lupi L, Zaccone G (2020) Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Link: https://bit.ly/2zIXOZc
Wang D, Hu B, Hu C (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 1061-1069. Link: https://bit.ly/2Wg8c2g
Lippi G, Lavie CJ, Sanchis-Gomar F (2020) Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. Link: https://bit.ly/35oPJoh
Yang X, Yu Y, Xu J (2020) Clinical course and outcomes of critically ill patients with SARS-CoV- 2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. Link: https://bit.ly/2KUsTM1
Welt FGP, Shah PB, Aronow HD, Bortnick AE, Henry TD, et al. (2020) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI), Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventional Council and SCAI, Journal of the American College of Cardiology. Link: https://bit.ly/2Sn2EC3
Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, et al. (2020) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. Link: https://bit.ly/2xrwiih
Behr ER, Roden D (2013) Drug-induced arrhythmia: pharmacogenomic prescribing? European Heart Journal 34: 89-95. Link: https://bit.ly/3aUNiLp
Tisdale JE, Jayes HA, Kingery JR (2013) Development and validation of a risk score to predict QT interval prolongation in shospitalized patients. Circ Cardiovasc Qual Outcomes6: 479-487. Link: https://bit.ly/35lSYNs
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. Link: https://bit.ly/2WkQbQm
Hongde Hu, Fenglian Ma, Wei X, Fang Y (2020) Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. Link: https://bit.ly/2YxiEFc
Chen L, Hao G (2020) The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease, Cardiovascular Research, cvaa093. Link: https://bit.ly/3fePkcz
Zheng Y, Ma Y, Zhang J (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17: 259-260. Link: https://bit.ly/2SrT2Wq
Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. Link: https://bit.ly/2L4LWDz
Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G (2020) Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients, European Heart Journal-Cardiovascular Pharmacotherapy, pvaa028. Link: https://bit.ly/3bZKP3y
de Simone G (2020) Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology. Link: https://bit.ly/2yjyn06
Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, et al. (2020) Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic, Journal of the American College of Cardiology. Link: https://bit.ly/2xop7XY
Rodríguez-Leor O (2020) Impact of the COVID-19 pandemic on care activity in interventional cardiology in Spain. REC Interv Cardiol.
Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet (London, England). 361: 13-20. Link: https://bit.ly/2VTELUP